TC BioPharm PLC, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is developing a streamlined and scaled-up manufacturing process that aims to increase its treatments capacity from 52 patient treatments per year to more than 1,000.   The objective of this undertaking, which will utilize the company’s current infrastructure, is to provide a cost reduction of 85% per patient treatment. The company expects to impl...